HER2-low breast cancer shows a lower immune response compared to HER2-negative cases

[1]  J. Ramos,et al.  Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers , 2021, Cancers.

[2]  M. Fassan,et al.  Evolution of HER2-low expression from primary to recurrent breast cancer , 2021, NPJ breast cancer.

[3]  P. Fasching,et al.  Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. , 2021, The Lancet. Oncology.

[4]  M. Balkenhol,et al.  Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study , 2021, Modern Pathology.

[5]  C. Sotiriou,et al.  HER2-Low Breast Cancer: Molecular Characteristics and Prognosis , 2021, Cancers.

[6]  N. Pondé,et al.  HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer , 2021, Breast Cancer Research and Treatment.

[7]  A. Lombardi,et al.  The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up , 2021, Breast cancer.

[8]  H. Iwata,et al.  The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status , 2021, Breast Cancer.

[9]  A. Lluch,et al.  Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer , 2021, NPJ breast cancer.

[10]  Qiuwen Tan,et al.  Predictive value of tumor‐infiltrating lymphocytes for response to neoadjuvant chemotherapy and breast cancer prognosis , 2020, Journal of surgical oncology.

[11]  Yonggang Zhang,et al.  The Novel Circular RNA Circ-PGAP3 Promotes the Proliferation and Invasion of Triple Negative Breast Cancer by Regulating the miR-330-3p/Myc Axis , 2020, OncoTargets and therapy.

[12]  A. Schneeweiss,et al.  Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer , 2020, Breast Cancer Research and Treatment.

[13]  F. Cardoso,et al.  HER2-Low Breast Cancer: Pathological and Clinical Landscape. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Sapino,et al.  Evolving concepts in HER2 evaluation in breast cancer: heterogeneity, HER2-low carcinomas and beyond. , 2020, Seminars in cancer biology.

[15]  Adel Assaf,et al.  Current and future directions , 2020, Dental Abstracts.

[16]  Zhongtao Zhang,et al.  Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis , 2019, BMC Cancer.

[17]  M. Smid,et al.  Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes , 2019, Clinical Cancer Research.

[18]  R. Gray,et al.  Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations , 2019, JNCI cancer spectrum.

[19]  R. Greil,et al.  HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer , 2019, International journal of molecular sciences.

[20]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Sanghui Park,et al.  Feasibility of Classification of Triple Negative Breast Cancer by Immunohistochemical Surrogate Markers , 2018, Clinical breast cancer.

[22]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[23]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Sleijfer,et al.  The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome , 2018, Cancers.

[25]  T. Tramm,et al.  Standardized assessment of tumor-infiltrating lymphocytes in breast cancer: an evaluation of inter-observer agreement between pathologists , 2018, Acta oncologica.

[26]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[27]  Sherene Loi,et al.  Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions , 2017, Front. Oncol..

[28]  Yan Gao,et al.  Down-regulation of MRPS23 inhibits rat breast cancer proliferation and metastasis , 2017, Oncotarget.

[29]  P. Moscato,et al.  Basal-like breast cancer: molecular profiles, clinical features and survival outcomes , 2017, BMC Medical Genomics.

[30]  T. Agatsuma,et al.  Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity , 2016, Cancer science.

[31]  T. Agatsuma,et al.  DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1 , 2016, Clinical Cancer Research.

[32]  Shellaine R. Frazier,et al.  Interobserver reproducibility for HER2/neu immunohistochemistry: A comparison of reproducibility for the HercepTest™ and the 4B5 antibody clone. , 2016, Pathology, research and practice.

[33]  M. Nerenberg,et al.  Loss of antigenicity with tissue age in breast cancer , 2016, Laboratory Investigation.

[34]  R. Gelber,et al.  Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  G. MacBeath,et al.  Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. , 2013, The American journal of pathology.

[37]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Matthew N. McCall,et al.  fRMA ST: frozen robust multiarray analysis for Affymetrix Exon and Gene ST arrays , 2012, Bioinform..

[39]  P. LoRusso,et al.  Results from a phase Ib study of trastuzumab emtansine (T-DM1), paclitaxel (T), and pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab. , 2012 .

[40]  T. Mukohara,et al.  Mediator Subunits MED1 and MED24 Cooperatively Contribute to Pubertal Mammary Gland Development and Growth of Breast Carcinoma Cells , 2012, Molecular and Cellular Biology.

[41]  J. Foekens,et al.  Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes , 2012, Breast Cancer Research and Treatment.

[42]  R. Lightowlers,et al.  Human ERAL1 is a mitochondrial RNA chaperone involved in the assembly of the 28S small mitochondrial ribosomal subunit , 2010, The Biochemical journal.

[43]  W. Gerald,et al.  Genes that mediate breast cancer metastasis to the brain , 2009, Nature.

[44]  W. Woodward,et al.  Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer , 2009, The American journal of surgical pathology.

[45]  Brad T. Sherman,et al.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.

[46]  Kelli Montgomery,et al.  Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis , 2009, BMC Cancer.

[47]  H. Tsuda,et al.  What causes discrepancies in HER2 testing for breast cancer? A Japanese ring study in conjunction with the global standard. , 2008, American Journal of Clinical Pathology.

[48]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[49]  H. Ishwaran,et al.  Lung metastasis genes couple breast tumor size and metastatic spread , 2007, Proceedings of the National Academy of Sciences.

[50]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[51]  C. Perou,et al.  Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma , 2006, Modern Pathology.

[52]  Andrew Glass,et al.  Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index , 2005, Modern Pathology.

[53]  J. Foekens,et al.  Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer , 2005, The Lancet.

[54]  J. Russo,et al.  Breast carcinoma malignancy grading by Bloom–Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index , 2005, Modern Pathology.

[55]  A. Gown,et al.  Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma , 2004, Clinical Cancer Research.

[56]  John J Spinelli,et al.  HER-2/neu in Breast Cancer: Interobserver Variability and Performance of Immunohistochemistry with 4 Antibodies Compared with Fluorescent In Situ Hybridization , 2001, Modern Pathology.